PROM1 and familial pancreatic carcinoma: Furthermore, Hermann and colleagues have shown that CD133+ pancreatic cancer cells are enriched in tumors after exposure to gemcitabine chemotherapy and are likely to resist therapy in comparison to CD133- negative cells26.